Skip Intro

FOG Pharmaceuticals, Inc.

In October 2016, Deerfield invested in FOG Pharmaceuticals, Inc. through its Series A preferred stock. FOG is an early-stage biotechnology company developing next-generation peptide inhibitors which target traditionally ‘undruggable’ intracellular protein-protein interactions.